Depreciation in USD of NGM BIOPHARMACEUTICALS INC from 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
NGM BIOPHARMACEUTICALS INC quarterly/annual Depreciation history and change rate from 2017 to Q4 2023.
  • NGM BIOPHARMACEUTICALS INC Depreciation for the quarter ending 31 Dec 2023 was $512,000.000, a 15.8% decline year-over-year.
  • NGM BIOPHARMACEUTICALS INC Depreciation for the twelve months ending 31 Dec 2023 was $2,221,000.000, a 45% decline year-over-year.
  • NGM BIOPHARMACEUTICALS INC annual Depreciation for 2023 was $2,221,000.000, a 45% decline from 2022.
  • NGM BIOPHARMACEUTICALS INC annual Depreciation for 2022 was $4,035,000.000, a 33.7% decline from 2021.
  • NGM BIOPHARMACEUTICALS INC annual Depreciation for 2021 was $6,089,000.000, a 7.11% decline from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

NGM BIOPHARMACEUTICALS INC Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 $2,221,000 $512,000 -$96,000 -15.8% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2024
Q3 2023 $2,317,000 $500,000 -$100,000 -16.7% 01 Jul 2023 30 Sep 2023 10-Q 02 Nov 2023
Q2 2023 $2,417,000 $600,000 -$800,000 -57.1% 01 Apr 2023 30 Jun 2023 10-Q 03 Aug 2023
Q1 2023 $3,217,000 $609,000 -$818,000 -57.3% 01 Jan 2023 31 Mar 2023 10-Q 04 May 2023
Q4 2022 $4,035,000 $608,000 -$827,000 -57.6% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2024
Q3 2022 $4,862,000 $600,000 -$900,000 -60% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023
Q2 2022 $5,762,000 $1,400,000 -$200,000 -12.5% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023
Q1 2022 $5,962,000 $1,427,000 -$127,000 -8.2% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q4 2021 $6,089,000 $1,435,000 -$89,000 -5.8% 01 Oct 2021 31 Dec 2021 10-K 11 Mar 2024
Q3 2021 $6,178,000 $1,500,000 -$100,000 -6.2% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 $6,278,000 $1,600,000 -$100,000 -5.9% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 $6,378,000 $1,554,000 -$177,000 -10.2% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 $6,555,000 $1,524,000 -$320,000 -17.4% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023
Q3 2020 $6,875,000 $1,600,000 -$300,000 -15.8% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 $7,175,000 $1,700,000 -$200,000 -10.5% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $7,375,000 $1,731,000 -$230,000 -11.7% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 $7,605,000 $1,844,000 -$36,000 -1.9% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022
Q3 2019 $7,641,000 $1,900,000 $0 0% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020
Q2 2019 $7,641,000 $1,900,000 +$200,000 +11.8% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020
Q1 2019 $7,441,000 $1,961,000 +$218,000 +12.5% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020
Q4 2018 $7,223,000 $1,880,000 01 Oct 2018 31 Dec 2018 10-K 15 Mar 2021
Q3 2018 $1,900,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $1,700,000 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019
Q1 2018 $1,743,000 01 Jan 2018 31 Mar 2018 10-Q 16 May 2019

NGM BIOPHARMACEUTICALS INC Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $2,221,000 -$1,814,000 -45% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2024
2022 $4,035,000 -$2,054,000 -33.7% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2024
2021 $6,089,000 -$466,000 -7.1% 01 Jan 2021 31 Dec 2021 10-K 11 Mar 2024
2020 $6,555,000 -$1,050,000 -13.8% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023
2019 $7,605,000 +$382,000 +5.3% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 $7,223,000 +$782,000 +12.1% 01 Jan 2018 31 Dec 2018 10-K 15 Mar 2021
2017 $6,441,000 01 Jan 2017 31 Dec 2017 10-K 17 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.